Contrasting of ContraFect Corporation (CFRX) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON)

ContraFect Corporation (NASDAQ:CFRX) and TRACON Pharmaceuticals Inc. (NASDAQ:TCON), are influenced by contrast since they are both players in the Biotechnology. These factors are particularly influence the institutional ownership, profitability, risk, analyst recommendations, dividends, earnings and valuation of the two firms.

Valuation and Earnings

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
ContraFect Corporation N/A 0.00 6.99M -0.52 0.00
TRACON Pharmaceuticals Inc. N/A 0.00 33.81M -1.35 0.00

Table 1 shows gross revenue, earnings per share and valuation of the two companies.

Profitability

Table 2 provides us the return on equity, return on assets and net margins of both businesses.

Net Margins Return on Equity Return on Assets
ContraFect Corporation 0.00% 0% -125.8%
TRACON Pharmaceuticals Inc. 0.00% -108% -67.3%

Volatility and Risk

ContraFect Corporation is 138.00% less volatile than S&P 500 due to its -0.38 beta. TRACON Pharmaceuticals Inc. on the other hand, has 2.69 beta which makes it 169.00% more volatile compared to S&P 500.

Liquidity

ContraFect Corporation has a Current Ratio of 5.4 and a Quick Ratio of 5.4. Competitively, TRACON Pharmaceuticals Inc.’s Current Ratio is 3 and has 3 Quick Ratio. ContraFect Corporation’s better ability to pay short and long-term obligations than TRACON Pharmaceuticals Inc.

Institutional and Insider Ownership

Roughly 55.7% of ContraFect Corporation shares are owned by institutional investors while 67.2% of TRACON Pharmaceuticals Inc. are owned by institutional investors. Insiders owned roughly 10% of ContraFect Corporation’s shares. Competitively, insiders own roughly 0.4% of TRACON Pharmaceuticals Inc.’s shares.

Performance

In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
ContraFect Corporation -6.32% -22.15% 22.31% -77.21% -72.28% -67.38%
TRACON Pharmaceuticals Inc. -4.23% 1.48% -33.98% -52.45% -72.24% 7.94%

For the past year ContraFect Corporation has -67.38% weaker performance while TRACON Pharmaceuticals Inc. has 7.94% stronger performance.

Summary

ContraFect Corporation beats on 4 of the 6 factors TRACON Pharmaceuticals Inc.

ContraFect Corporation, a clinical-stage biotechnology company, focuses on discovering and developing therapeutic protein and antibody products for the treatment of life-threatening infectious diseases in the United States. Its lead product candidates consist of CF-301, a lysin that completed Phase 1 human clinical trials for the treatment of Staph aureus bacteremia, including endocarditis caused by methicillin-resistant or methicillin-susceptible Staph aureus; and CF-404, a combination of human monoclonal antibodies (mAbs) for the treatment of life-threatening seasonal and pandemic varieties of human influenza. The company has a collaboration research agreement with The Rockefeller University to identify new lysin therapeutic candidates targeting Gram-negative bacteria; and license agreement with Trellis Bioscience LLC for mAbs in the field of influenza. ContraFect Corporation was founded in 2008 and is headquartered in Yonkers, New York.

TRACON Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for cancer, wet age-related macular degeneration (AMD), and fibrotic diseases. Its lead product candidate is TRC105, an endoglin antibody, which is in Phase III clinical trials for angiosarcoma; randomized Phase II clinical trials for renal cell carcinoma; Phase II clinical trials for soft tissue sarcoma; Phase II clinical trials for gestational trophoblastic neoplasia; Phase I/II clinical trials for hepatocellular carcinoma; Phase I clinical trial for lung cancer; Phase I/II clinical trials for breast cancer; and Phase I/II clinical trials for wet AMD. The companyÂ’s other product candidates comprise TRC102, a small molecule that is in Phase II clinical trials for mesothelioma, Phase II clinical trials for glioblastoma, Phase I clinical trial for solid tumors and lymphomas, as well as Phase I clinical trial for lung cancer; and TRC253, a small molecule high affinity competitive inhibitor of wild type androgen receptor (AR) and multiple AR mutant receptors that is in Phase I/II clinical trials for the treatment prostate cancer. Its preclinical development products include TRC205, an endoglin antibody for the treatment of fibrotic diseases; and TRC694, an orally bioavailable inhibitor of NF-kB inducing kinase for the treatment of patients with hematologic malignancies, including myeloma. The company has a strategic licensing collaboration with Janssen Pharmaceutica N.V. to develop TRC253 and TRC694; and a license agreement with Santen Pharmaceutical Co., Ltd to develop, manufacture, and commercialize DE-122, the ophthalmic formulation of TRC105, for ophthalmology indications. The company was formerly known as Lexington Pharmaceuticals, Inc. and changed its name to TRACON Pharmaceuticals, Inc. in March 2005. TRACON Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.